Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
20.56
+0.45 (2.21%)
Oct 8, 2025, 10:15 AM EDT - Market open
Enliven Therapeutics Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$41.20
Upside
+100.44%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $48 | Strong Buy | Maintains | $40 → $48 | +133.52% | Jul 2, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +80.00% | Jun 16, 2025 |
Baird | Baird | Buy Maintains $40 → $52 | Buy | Maintains | $40 → $52 | +152.98% | Jun 16, 2025 |
Jones Trading | Jones Trading | Strong Buy Maintains $36 → $27 | Strong Buy | Maintains | $36 → $27 | +31.35% | May 16, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +94.60% | May 15, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $37 → $39 | Strong Buy | Maintains | $37 → $39 | +89.73% | Mar 21, 2025 |
BTIG | BTIG | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +104.33% | Dec 13, 2024 |
Baird | Baird | Buy Maintains $32 → $40 | Buy | Maintains | $32 → $40 | +94.60% | Nov 15, 2024 |
Jones Trading | Jones Trading | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +75.14% | Oct 31, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +80.00% | Oct 1, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +80.00% | Sep 9, 2024 |
Baird | Baird | Buy Initiates $32 | Buy | Initiates | $32 | +55.68% | Jun 11, 2024 |
Mizuho | Mizuho | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +65.41% | Apr 9, 2024 |
Jefferies | Jefferies | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +31.35% | Mar 29, 2023 |
TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 3, 2023 |